Fulcrum Therapeutics announced it will host a conference call and webcast on Tuesday, July 29, 2025, to present topline results from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease.
Members of Fulcrum management will be joined by Dr. Sheinei Alan, Director of the Inova Fairfax Adult Sickle Cell Program, and Dr. Wally Smith, Director at the VCU Adult Sickle Cell Program, to discuss the findings.
This upcoming presentation is a key event for investors, as it will provide the first detailed look at the efficacy and safety data from this important dose cohort for pociredir.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.